VivoSeq
Other

Sts

0

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Sts is an early-stage landscape with 0 programs across 3 companies. The most active players are Boehringer Ingelheim, Staidson (Beijing) Biopharmaceuticals Co., Ltd, Monopar Therapeutics.

Intelligence

Pipeline Metrics

Competitive Density

10/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

83/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

0 programs

PreclinicalS

Staidson (Beijing) Biopharmaceuticals Co., Ltd

0 programs

PreclinicalM

Monopar Therapeutics

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

29

clinical trials

Completed20 · 69%
Terminated4 · 14%
Unknown status3 · 10%
Active, not recruiting1 · 3%
Recruiting1 · 3%

Clinical Trials

Trial Activity

29 trials

A Study to Evaluate the Safety and Tolerability of Multiple Dose of STSP-0902 in Healthy Subjects
Recruiting·SStaidson (Beijing) Biopharmaceuticals Co., Ltd·Phase 1·NCT06948799·48 enrolled
A Study of STSP-0902 Ophthalmic Solution in Healthy Subjects
Active, not recruiting·SStaidson (Beijing) Biopharmaceuticals Co., Ltd·Phase 1·NCT06597422·80 enrolled
This Study Tests BI 1467335 in Healthy Male Volunteers. The Study Tests How Different Doses of BI 1467335 Are Taken up and Handled by the Body
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT03382509·16 enrolled
A Study of STSA-1201 in Healthy Subjects
Completed·SStaidson (Beijing) Biopharmaceuticals Co., Ltd·Phase 1·NCT05986877·44 enrolled
Safety Study of Maraviroc's Effect on Human Osteoclasts
Completed·NNational Center for Global Health and Medicine, Japan·N/A·NCT01428986·16 enrolled
This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT03315936·68 enrolled
A Study of STSA-1002 in Healthy Subjects
Completed·SStaidson (Beijing) Biopharmaceuticals Co., Ltd·Phase 1·NCT05497635·26 enrolled
Effect of Flavonoids on Gut Permeability in Cyclists
Completed·UUtah State University·Phase 1·NCT03427879·12 enrolled
This Study in Healthy Men Tests How Itraconazole Influences the Amount of BI 1015550 in the Blood
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT03403439·16 enrolled
This Study Tests BI 1467335 in Healthy Japanese and Caucasian Men. The Study Tests How Different Doses of BI 1467335 Are Taken up in the Body and How Well They Are Tolerated
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT03159455·48 enrolled
The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil
Completed·—·Phase 4·NCT03144596·63 enrolled
Effects of Substance P Antagonists on Adrenal Secretion
Completed·UUniversity Hospital, Rouen·Phase 4·NCT00977223·20 enrolled
This Study in Healthy Men Tests How Different Doses of BI 1323495 Are Taken up in the Body and How Well They Are Tolerated.
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT03588390·63 enrolled
This Study in Healthy Men Tests How Different Doses of BI 1265162 Are Taken up in the Body and How Well They Are Tolerated.
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT03576144·50 enrolled
This Study Tests the Safety, Tolerability and How Different Doses of BI 1265162 Are Taken up in the Body of Healthy Men
Completed·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 1·NCT03349723·57 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)